Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenstrom's Macroglobulinemia
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Rituximab
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 16 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2018 Planned End Date changed from 1 Dec 2022 to 1 Sep 2023.
- 16 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.